Italy Insulin Drugs And Delivery Devices Market Size (2024 - 2029)

The Italy Insulin Drugs and Delivery Devices Market is projected to experience growth over the forecast period, driven by advancements in technology and the adoption of innovative devices that offer greater comfort to patients. The market's expansion is supported by the country's healthcare framework, which provides essential medical assistance, including free insulin pens for diabetic patients, while adhering to specific guidelines. Additionally, initiatives to enhance health literacy and urban health programs contribute to the overall market dynamics, reflecting a structured approach to healthcare delivery across different regions in Italy.

Market Size of Italy Insulin Drugs And Delivery Devices Industry

Italy Insulin Drugs and Delivery Devices Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 531.86 Million
Market Size (2029) USD 572.96 Million
CAGR (2024 - 2029) 1.50 %

Major Players

Italy Insulin Drugs and Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Italy Insulin Drugs and Delivery Devices Market Analysis

The Italy Insulin Drugs And Delivery Devices Market size is estimated at USD 531.86 million in 2024, and is expected to reach USD 572.96 million by 2029, growing at a CAGR of 1.5% during the forecast period (2024-2029).

The insulin drugs and delivery devices market in Italy is experiencing significant growth, driven by the rising prevalence of diabetes and advancements in technology. According to the International Diabetes Federation (IDF), Italy's diabetic population is expected to increase from 4,470.3 thousand in 2021 to around 4,699.1 thousand by 2030.

Italy's National Healthcare Service (NHS) stands out for its commitment to universal healthcare, ensuring that citizens, especially those with diabetes (PwD), have unfettered access to essential medicines, devices, and medical services, all without incurring any out-of-pocket expenses. This robust system is further bolstered by the presence of numerous diabetes centers across the country, offering free treatment at the point of delivery.

The insulin devices market in Italy is witnessing a surge in technological advancements. These innovations have not only introduced more comfortable devices for patients but have also paved the way for new, more patient-friendly options. For instance, in March 2024, at the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, Insulet Corporation showcased promising results from a clinical trial comparing its Omnipod 5 to non-automated insulin therapy. The study revealed that Omnipod 5 users experienced a 17.5% improvement in their time in the target glucose range, along with reduced HbA1c levels and less time spent in hypoglycemia. Notably, individuals with initially higher HbA1c levels also saw a decrease in their mean glucose levels, further underscoring the benefits of these advanced products in the Italian market.

Italy's insulin drugs and delivery devices market is poised for continued growth, driven by increasing diabetes prevalence and significant technological advancements. The commitment of the Italian National Healthcare Service to provide comprehensive care for people with diabetes further supports market expansion.

Italy Insulin Drugs and Delivery Devices Industry Segmentation

Insulin is administered to regulate blood sugar levels in individuals diagnosed with type 1 diabetes, a condition characterized by the body's inability to produce insulin and consequently unable to regulate blood sugar levels. It is also prescribed for individuals with type 2 diabetes, a condition where blood sugar levels are elevated due to the body's inadequate production or utilization of insulin, and oral medications alone are insufficient in managing the condition. There are several ways to give insulin subcutaneously, including a vial and syringe, an insulin pen, and continuous subcutaneous insulin infusion (CSII).

Italy's insulin drugs and delivery devices market is segmented by drugs and devices. By drugs, the market is segmented into basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, and others. By devices, the market is segmented into insulin pens, insulin pumps, and insulin syringes. For each segment, the market size is provided in terms of value (USD).

By Drug
Basal Or Long-Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Others
Bolus Or Fast-Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Others
Traditional Human Insulins
Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Others
By Device
Insulin Pumps
Insulin Pens
Insulin Syringes
Need A Different Region Or Segment?
Customize Now

Italy Insulin Drugs And Delivery Devices Market Size Summary

The Italy Insulin Drugs and Delivery Devices Market is poised for steady growth over the forecast period, driven by advancements in technology and a well-structured healthcare system. The market benefits from the Italian National Healthcare Service's universal coverage, ensuring that individuals with diabetes have access to necessary medications and devices without out-of-pocket expenses. The decentralized nature of the Italian health system, with significant administrative powers held by regional authorities, allows for tailored diabetes care strategies. The National Diabetes Plan further enhances the quality of care by focusing on patient-centered approaches. Technological innovations in insulin delivery devices, such as insulin pumps, are gaining traction due to their ability to provide continuous and more accurate insulin administration, reducing the discomfort and variability associated with traditional methods.

The market landscape is characterized by a consolidated structure with a few major players, including Roche, Medtronics, Novo Nordisk, Sanofi, and Eli Lilly. Recent mergers and collaborations, such as those between Eli Lilly and Boehringer Ingelheim, and Novo Nordisk and Ypsomed, have strengthened the market presence of these companies. The development of integrated automated insulin delivery systems, like the one announced by CamDiab and Ypsomed, highlights the ongoing commitment to enhancing diabetes management through smart, connected solutions. These advancements are expected to drive the adoption of insulin delivery devices, contributing to the market's growth trajectory in Italy.

Explore More

Italy Insulin Drugs And Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Strategic Initiatives By The Government and Organizations

      2. 1.2.2 Increasing Prevalence Of Diabetes In Italy

    3. 1.3 Market Restraints

      1. 1.3.1 Limited Availability of Affordable Drug Delivery Devices In The Country

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size By Value - USD)

    1. 2.1 By Drug

      1. 2.1.1 Basal Or Long-Acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Others

      2. 2.1.2 Bolus Or Fast-Acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.1.2.2 Humalog (Insulin Lispro)

        3. 2.1.2.3 Apidra (Insulin Glulisine)

        4. 2.1.2.4 Others

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Mixtard/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Others

    2. 2.2 By Device

      1. 2.2.1 Insulin Pumps

      2. 2.2.2 Insulin Pens

      3. 2.2.3 Insulin Syringes

Italy Insulin Drugs And Delivery Devices Market Size FAQs

The Italy Insulin Drugs And Delivery Devices Market size is expected to reach USD 531.86 million in 2024 and grow at a CAGR of 1.5% to reach USD 572.96 million by 2029.

In 2024, the Italy Insulin Drugs And Delivery Devices Market size is expected to reach USD 531.86 million.

Italy Insulin Drugs and Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)